Product Description
Mechanisms of Action: MECP2 Modulator
Novel Mechanism: Yes
Modality: Nucleic Acid
Route of Administration: Injection
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Ionis
Company Location: CARLSBAD CA 92010
Company CEO: Brett P. Monia
Additonal Commercial Interests: None
Clinical Description
![Map of Global Clinical Trials for ION-440](https://pryzm-maps.s3.us-west-2.amazonaws.com/666666current_maps.png)
Countries in Clinic: Spain
Active Clinical Trial Count: 2
Highest Development Phases
Phase 2: Myelodysplastic Syndrome|Rett Syndrome
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
ION440-CS1 | P2 |
Not yet recruiting |
Myelodysplastic Syndrome |
2030-04-22 |
|
ATTUNE | P2 |
Not yet recruiting |
Rett Syndrome |
2026-05-01 |
24% |